Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

BACKGROUND: Label-retaining cancer cells (LRCC) have been proposed as a model of slowly cycling cancer stem cells (CSC) which mediate resistance to chemotherapy, tumor recurrence, and metastasis. The molecular mechanisms of chemoresistance in LRCC remain to-date incompletely understood. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dandan, Mullinax, John E., Aiken, Taylor, Xin, Hongwu, Wiegand, Gordon, Anderson, Andrew, Thorgeirsson, Snorri, Avital, Itzhak, Rudloff, Udo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069886/
https://www.ncbi.nlm.nih.gov/pubmed/30064387
http://dx.doi.org/10.1186/s12885-018-4690-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069886/
https://www.ncbi.nlm.nih.gov/pubmed/30064387
http://dx.doi.org/10.1186/s12885-018-4690-1

Ejemplares similares